Indication

Prophylaxis of migraine in adults who have at least 4 migraine days per month

Medicine details

Medicine name:
galcanezumab (Emgality)
SMC ID:
SMC2313
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
12 April 2021
SMC meeting date:
02 March 2021
Patient group submission deadline:
01 February 2021